Aurora Cannabis Q3 Results Highlight Record Medical Revenue and Strategic Refocus on Core Markets
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aurora Cannabis ( (TSE:ACB) ) has provided an update.
For its fiscal third quarter ended December 31, 2025, Aurora Cannabis reported a 7% year-over-year increase in total net revenue to $94.2 million, driven by a 12% rise in global medical cannabis revenue to a record $76.2 million and 27% growth in its plant propagation business, partly offset by weaker Canadian consumer cannabis sales. Consolidated adjusted gross margin before fair value adjustments remained robust at 62%, while adjusted EBITDA came in at $18.5 million and adjusted net income was $7.2 million, with free cash flow of $15.5 million and a strong cash position of $154.4 million supporting a largely debt-free cannabis operation. Despite the solid underlying performance, the company posted a small net loss from continuing operations of $1.7 million, reflecting lower gross profit and higher operating expenses compared with the prior-year period. Strategically, Aurora is doubling down on its core medical cannabis franchise: starting in the fourth quarter of fiscal 2026 it will exit selected low-margin Canadian recreational markets to redeploy product and resources into higher-margin medical channels, a move it expects will reduce SG&A, improve gross margins and lift adjusted EBITDA over coming quarters. In plant propagation, Aurora agreed on February 3, 2026 to exchange its common equity in Bevo Agtech for preferred shares that provide a 5% annual dividend, a structured share of Bevo’s cash flows and liquidation proceeds, and customary protective rights, while relinquishing board representation—effectively shifting from an operating stake to a yield-focused financial interest in the asset and further sharpening Aurora’s focus on its core medical cannabis growth strategy.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Spark’s Take on TSE:ACB Stock
According to Spark, TipRanks’ AI Analyst, TSE:ACB is a Neutral.
Aurora Cannabis faces significant financial challenges, with ongoing losses and cash flow issues weighing heavily on its score. While recent earnings call highlights and strategic investments in international markets provide some optimism, the overall outlook remains cautious due to valuation concerns and technical indicators suggesting bearish momentum.
To see Spark’s full report on TSE:ACB stock, click here.
More about Aurora Cannabis
Aurora Cannabis Inc. is a Canada-based global medical cannabis company that focuses on high-margin prescription cannabis products for international and domestic patients, supported by GMP-certified cultivation and manufacturing facilities, proprietary genetics and scientific capabilities. While it maintains a smaller Canadian consumer cannabis segment and a plant propagation business, the company is increasingly orienting its operations and capital toward regulated medical markets such as Germany, Poland, and Australia, where insurance coverage and pricing dynamics support stronger margins and cash generation.
Average Trading Volume: 556,396
Technical Sentiment Signal: Sell
Current Market Cap: C$305.1M
For detailed information about ACB stock, go to TipRanks’ Stock Analysis page.
